NCT01366547 - Relative Bioavailability Study of Two New Dolutegravir/Abacavir/Lamivudine Fixed Dose Combination Tablets | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 30, 2011

Primary Completion Date

July 31, 2011

Study Completion Date

July 31, 2011

Conditions

Healthy SubjectsInfection, Human Immunodeficiency Virus

Interventions

DRUG

Dolutegravir 50 mg/abacavir 600 mg/lamivudine 300 mg

Dolutegravir 50 mg/abacavir 600 mg/lamivudine 300 mg is an experimental fixed dose combination tablet of an experimental integrase inhibitor (dolutegravir) and two FDA approved nucleoside reverse transcriptase inhibitors (abacavir and lamivudine)

DRUG

Dolutegravir 50 mg

Dolutegravir is an experimental drug in the integrase inhibitor class that is being studied for the treatment of HIV infection.

DRUG

abacavir 600 mg/lamivudine 300 mg

This is an FDA approved fixed dose combination tablet of two nucleoside reverse transcriptase inhibitors

Trial Locations (1)

14202

GSK Investigational Site, Buffalo